Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.622    
  

February 16,
2001 

John
Anthony Lambert

Box Cottage—Church Lane

Great Kimble—Aylesbury

Bucks HP17 9th 

Dear
John: 

        I
am pleased to confirm our offer to you as President of Chiron Vaccines. Your base salary will be £185,000. This salary will be reviewed from time to time and adjusted in
line with your performance and market information. In addition, we will provide an automobile for your use while employed by Chiron. You will be payrolled by the Chiron BioPharmaceuticals London
office and your home base will be considered England. 

        Should
Chiron Vaccines establish an office in the U.K., the legal entity might change but not the basic terms of employment. As we have discussed the job will require your active
presence in Marburg and Siena to oversee the business as well as regular trips to Emeryville. 

        You
win be eligible to participate in the Annual Incentive Plan (AlP) that covers Chiron Executive Committee members. Your position has a target of 60% of base salary. The actual amount
may vary annually from no bonus to 120% of base salary. The amount actually paid depends upon the performance of Chiron Corporation, the Vaccines business. and your own performance. Any bonus for 2001
may be prorated based on your employment during 2001. Bonuses are payable in March following the end of the performance year. 

        You
will be eligible to participate in our stock option program. Subject to the approval of the Board of Directors, you will be awarded a stock option grant to purchase 200,000 shares of
Chiron common stock. The options vest fully over a four-year period, with the first 25% of the shares vesting at the one-year grant anniversary. Shares vest on a
pro-rated monthly basis over the remaining three years of
the vesting period. The exercise price of the option will be set at the fair market value (as defined in the Option Plan) of a share of Chiron stock on the date the option is approved. We expect the
options will be approved and effective within 30 days of your employment date. Assuming you take up employment on or around March 5, 2001, you will be eligible to participate in the
Executive Long Term Incentive Program. You will be eligible for a pro-rated performance-based annual stock option grant in 2002. 

        In
the event your employment is severed by Chiron for reason other than cause, you will be eligible for a minimum severance benefit of two years of base salary plus bonus, the bonus
portion being calculated as the average of the prior 2 years bonus payments. This benefit is in lieu of or offset by any other Chiron severance plan payments you might be due under any
plans—U.K. or U.S. 

        You
will be eligible for benefits offered by Chiron in the U.K. We will endeavor to set up an appropriate arrangement for a pension contribution by the company of £30,000 per
annum. 

        As
mentioned above, this is intended to put the substantive points of an employment offer to you. Anytime contract will be put in a form consistent with U.K. custom, but without changing
the agreed upon terms. 

        The
Chiron Management team looks forward to you joining us as we believe you will make an excellent contribution in leading the Vaccines business. 

	Sincerely yours,	 	 
	

 

Seán P. Lance

Chairman and Chief Executive OffIcer	
 	

 
	

SPL:ptr	
 	

 
	 	 	I accept the above offer and terms.
	

 	
 	

/s/ John A. Lambert
 18th February 2001

QuickLinks

Exhibit 10.622QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.726    
  

 
 

NOVARTIS AG
  
    WRITTEN CONSENT AND APPROVAL
  
    Effective as of February 21, 2003    

CHANGES IN THE NAME AND COMPOSITION OF THE NOMINATING COMMITTEE; AMENDMENT TO GOVERNANCE AGREEMENT  

        WHEREAS, Section 2.04 (a)(iv) of that certain Governance Agreement dated as of November 20, 1994, as amended (the "Governance Agreement"),
between Chiron Corporation ("Chiron" or the "Company") and Novartis AG ("Novartis") as successor-in-interest to Ciba-Geigy Limited, requires the approval of
Novartis of any change in the size or composition of any committee of the Board of Directors of Chiron; 

        WHEREAS,
the Company has established a Nominating Committee (the "Committee") of the Board of Directors of Chiron; 

        WHEREAS,
at the February 21, 2003 meeting of the independent directors, the non-management directors recommended that it would be in the best interests of the Company
to: (i) amend Section 2.03(b)(ii) of the Governance Agreement to eliminate the requirement that the Committee include a Management Director (as defined in the Governance
Agreement) and to include an additional Independent Director (as defined in the Governance Agreement) instead; and (ii) approve a change in the name of the committee from "Nominating Committee"
to "Nominating and Corporate Governance Committee" in light of the proposed changes to the corporate governance rules of The Nasdaq Stock Market and the New York Stock Exchange; 

        WHEREAS,
the proposed changes would require the consent of Novartis under Section 2.04(a)(iv) and (vi) of the Governance Agreement and Novartis has determined to
enter into an Amendment to Governance Agreement with Chiron to effect that change; 

        NOW,
THEREFORE, BE IT RESOLVED, that Novartis hereby consents to the proposed changes in the composition of the Nominating Committee contemplated by the form of Amendment to the
Governance Agreement in substantially the form attached hereto as Addendum 1, and the change in the name of the committee to "Nominating and Corporate
Governance Committee", effective as of February 21, 2003. 

	 	 	NOVARTIS AG
	

 	
 	

By:	
 	

/s/  P. RUPPRECHT      
	 	 	Its:	 	 
	 	 	 	 	
 Peter Rupprecht

authorized signatory
	

 	
 	

By:	
 	

/s/  BREU      
	 	 	Its:	 	CFO
	 	 	 	 	

 
 
 

ADDENDUM 1
  
    AMENDMENT TO GOVERNANCE AGREEMENT    

        AMENDMENT
TO GOVERNANCE AGREEMENT dated as of                        , 2003 (this "Amendment") to the Governance Agreement dated as of
November 20, 1994, as amended (the "Agreement"), by
and between Chiron Corporation, a Delaware corporation ("Chiron"), and Novartis AG as successor in interest to Ciba-Geigy Limited ("Novartis"). 

        WHEREAS,
Section 2.03 of the Agreement provides for, among other things, a Nominating Committee and specifies the number of members on the Nominating Committee who are to be
"Investor Directors," "Independent Directors" and "Management Directors" (as each such term is defined in the Agreement) and the parties now desire to amend the Agreement to clarify that the
Nominating Committee shall consist of only Investor Directors and Independent Directors. 

        NOW,
THEREFORE, in consideration of the promises and mutual covenants herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, it is mutually agreed by the parties as follows: 

        1.    Amendment to Section 2.03(b)(ii).    Section 2.03(b)(ii) of the Agreement is hereby amended
by deleting such clause in its entirety and replacing it with the following language: 

        (ii)  a
Nominating Committee, responsible, among other things, for recommending the nomination of Directors, all pursuant to Section 2.01, and comprised and conducting
itself as follows: 

        (A)  if
Ciba's Percentage Interest is less than 40%, the Nominating Committee shall be comprised of three Independent Directors and one Investor Director; 

        (B)  so
long as Ciba's Percentage Interest is at least 40%, the Nominating Committee shall be composed of three Independent Directors and two Investor Directors; 

        (C)  a
majority of the Independent Directors shall designate the Independent Directors that serve on the Nominating Committee and a majority of the Investor Directors shall
designate the Investor Directors that serve on the Nominating Committee; 

        (D)  a
quorum of the Nominating Committee required for any action thereby shall require the attendance of each member thereof; and 

        (E)  the
Nominating Committee shall act by majority vote of the entire Nominating Committee; provided, however, that (1) so long as Ciba's Percentage Interest is at
least 40%, no action may be taken by the Nominating Committee that is opposed by both of the Investor Directors; and (2) in addition on and after the eleventh anniversary of the Effectiveness
of this Agreement, so long as Ciba's Percentage Interest is at least 49%, the Investor Director members shall have a deciding vote (meaning that, with respect to any motion before the committee, if
the two Investor Director members vote one way, the vote of the Investor Directors will control regardless of the vote of the Independent Directors); 

        2.    No Further Changes.    Except as otherwise provided herein, the Agreement shall remain in full force and effect. 

2

 

        IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above. 

	 
	 	 
	 	 

	 	 	CHIRON CORPORATION
	

 	
 	

By:	
 	

 
	 	 	 	 	

	 	 	Name:

Title:
	

 	
 	

NOVARTIS AG
	

 	
 	

By:	
 	

 
	 	 	 	 	

	 	 	Name:

Title:
	

 	
 	

By:	
 	

 
	 	 	 	 	

	 	 	Name:

Title:

3

QuickLinks

Exhibit 10.726

NOVARTIS AG WRITTEN CONSENT AND APPROVAL Effective as of February 21, 2003

ADDENDUM 1 AMENDMENT TO GOVERNANCE AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.727    
  

 
 

AMENDMENT TO GOVERNANCE AGREEMENT    

        AMENDMENT
TO GOVERNANCE AGREEMENT dated as of March 11, 2003 (this "Amendment") to the Governance Agreement dated as of November 20, 1994, as amended (the "Agreement"), by
and between Chiron Corporation, a Delaware corporation ("Chiron"), and Novartis AG as successor in interest to Ciba-Geigy Limited ("Novartis"). 

        WHEREAS,
Section 2.03 of the Agreement provides for, among other things, a Nominating Committee and specifies the number of members on the Nominating Committee who are to be
"Investor Directors," "Independent Directors" and "Management Directors" (as each such term is defined in the Agreement) and the parties now desire to amend the Agreement to clarify that the
Nominating Committee shall consist of only Investor Directors and Independent Directors. 

        NOW,
THEREFORE, in consideration of the promises and mutual covenants herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, it is mutually agreed by the parties as follows: 

        1.    Amendment to Section 2.03(b)(ii).    Section 2.03(b)(ii) of the Agreement is hereby amended
by deleting such clause in its entirety and replacing it with the following language: 

        (ii)  a
Nominating Committee, responsible, among other things, for recommending the nomination of Directors, all pursuant to Section 2.01, and comprised and conducting
itself as follows: 

        (A)  if
Ciba's Percentage Interest is less than 40%, the Nominating Committee shall be comprised of three Independent Directors and one Investor Director; 

        (B)  so
long as Ciba's Percentage Interest is at least 40%, the Nominating Committee shall be composed of three Independent Directors and two Investor Directors; 

        (C)  a
majority of the Independent Directors shall designate the Independent Directors that serve on the Nominating Committee and a majority of the Investor Directors shall
designate the Investor Directors that serve on the Nominating Committee; 

        (D)  a
quorum of the Nominating Committee required for any action thereby shall require the attendance of at least two Independent Directors and both Investor Director
members thereof; and 

        (E)  the
Nominating Committee shall act by majority vote of the entire Nominating Committee; provided, however, that (1) so long as Ciba's Percentage Interest is at
least 40%, no action may be taken by the Nominating Committee that is opposed by both of the Investor Directors; and (2) in addition on and after the eleventh anniversary of the Effectiveness
of this Agreement, so long as Ciba's Percentage Interest is at least 49%, the Investor Director members shall have a deciding vote (meaning that, with respect to any motion before the committee, if
the two Investor Director members vote one way, the vote of the Investor Directors will control regardless of the vote of the Independent Directors); 

        2.    No Further Changes.    Except as otherwise provided herein, the Agreement shall remain in full force and effect. 

 

        IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above. 

	 
	 	 
	 	 

	 	 	CHIRON CORPORATION
	

 	
 	

By:	
 	

/s/  WILLIAM G. GREEN      

	 	 	Name:	 	William G. Green
	 	 	Title:	 	Sr. Vice President, General Counsel and Secretary
	

 	
 	

NOVARTIS AG
	

 	
 	

By:	
 	

/s/  P. RUPPRECHT      

	 	 	Name:	 	Peter Rupprecht
	 	 	Title:	 	authorized signatory
	

 	
 	

By:	
 	

/s/  BREU      

	 	 	Name:	 	[Raymund Breu]
	 	 	Title:	 	CFO

2

QuickLinks

Exhibit 10.727

AMENDMENT TO GOVERNANCE AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]